Article Text

PDF
Response to: ‘Response to: ‘Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al’ by Isenberg
  1. Eric F Morand1,
  2. Teodora Trasieva2,
  3. Anna Berglind2,
  4. Gabor Illei3,
  5. Raj Tummala2
  1. 1 School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
  2. 2 AstraZeneca, Gothenburg, Sweden
  3. 3 Clinical Development, Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, USA
  1. Correspondence to Professor Eric F Morand, School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Victoria 3168, Australia; eric.morand{at}monash.edu

Statistics from Altmetric.com

The authors thank Professor Isenberg1 for pointing out a drafting error on the manuscript reporting the use of the Lupus Low Disease Activity State (LLDAS) …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles